Structure Therapeutics (NASDAQ:GPCR) Shares Up 4.8% – Time to Buy?

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) rose 4.8% during trading on Friday . The stock traded as high as $48.60 and last traded at $48.2490. 283,921 shares changed hands during mid-day trading, a decline of 70% from the average daily volume of 933,298 shares. The stock had previously closed at $46.03.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on GPCR shares. Wall Street Zen downgraded shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Wolfe Research started coverage on shares of Structure Therapeutics in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. Canaccord Genuity Group began coverage on Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 target price on the stock. HC Wainwright reduced their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $110.55.

Structure Therapeutics Stock Up 5.3%

The stock’s 50-day moving average price is $44.34 and its 200 day moving average price is $56.52. The company has a market cap of $3.45 billion, a P/E ratio of -55.72 and a beta of -1.50.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. Analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GPCR. CWM LLC boosted its position in shares of Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 125 shares during the period. Sterling Capital Management LLC bought a new position in Structure Therapeutics during the first quarter worth $28,000. State of Wyoming bought a new position in Structure Therapeutics during the second quarter worth $28,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Structure Therapeutics during the 4th quarter valued at $127,000. Finally, Assetmark Inc. raised its stake in Structure Therapeutics by 21.4% during the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after purchasing an additional 449 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.